As IRA drug pricing provisions take shape, market dynamics will change in ways that will likely yield downward pressure, at least on the prices of existing cancer drugs.
Maia Kayal, MD, MS, and Kimberly C. Chen, DO, MSHLM, discuss challenges for biosimilars with interchangeable designation related to automatic substitution in the pharmacy.
Agency: " Centers for Medicare& Medicaid Services, Department of Health and Human Services." This final rule finalizes certain 2021 and 2022 Star Ratings provisions that were included in two interim final rules with comment period that CMS issued on April 6, 2020, and September 2, 2020; other policies from those interim final rules will be addressed in other.